Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Wen leaving Invitae as CFO

Plus: Fenton succeeds CEO Requadt at Talaris, and an update from Sera

May 26, 2023 11:04 PM UTC

Genetic testing company Invitae Corp. (NYSE:NVTA) named Christine Gorjanc as interim CFO, effective July 1, following the resignation of CFO Yafei Wen who is leaving to pursue other opportunities. Gorjanc has served on the company’s board and as chair of the audit committee since November 2015. 

Scott Requadt is leaving  Talaris Therapeutics Inc. (NASDAQ:TALS) as CEO as part of a planned workforce reduction announced in April. The cell therapy company is considering strategic alternatives, including a possible business combination and divestiture of its cell therapy CMC capabilities. CFO Mary Fenton was named interim president and CEO...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article